Introduction {#s1}
============

Mechanistic target of rapamycin (mTOR) plays an essential role in sensing a myriad of environmental cues including nutrients and growth factor stimulation to regulate cell growth and proliferation ([@bib40]). mTOR independently associates with raptor or rictor to form two distinct complexes, mTORC1 and mTORC2, respectively. The two complexes share several common subunits, including the catalytic mTOR subunit, mLST8, DEPTOR, and the Tti1/Tel2 complex ([@bib23]). Among the remaining components, PRAS40 are specific to mTORC1, whereas rictor, mSin1 protor1/2 are unique to mTORC2 ([@bib23]). These two complexes differ in their sensitivity to rapamycin, upstream signals and downstream outputs ([@bib23]). The mTORC1 complex integrates different extracellular and intracellular signal inputs, such as growth factors, amino acids, stress and energy status, to regulate cellular processes such as protein and lipid synthesis and autophagy, by phosphorylating and activating p70 S6 kinase (p70S6K) ([@bib5]; [@bib30]) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) ([@bib24]; [@bib36]). In contrast, mTORC2 is involved in Akt phosphorylation and regulation of the cellular cytoskeleton ([@bib1]). Activation of mTORC1 by amino acids requires the translocation of mTORC1 from the cytosol to the surface of lysosomes, which is dependent on the Rag GTPase heterodimers RagA/B and RagC/D ([@bib21]; [@bib32]).

The second messenger calcium has been shown to play an important role in the regulation of mTOR signaling. Earlier hints that calcium might be involved in mTOR signaling came from observations that calcium was required for the activation of p70S6K ([@bib6]; [@bib12]; [@bib15]). But the underlying mechanism was attributed to upstream regulators such as PI3K or isoforms of PKC. More definitive roles of calcium and its signaling mediator calmodulin (CaM) in mTORC1 signaling were demonstrated in the context of amino acid activation of the pathway ([@bib14]). It was shown that the phosphorylation of S6K1 in response to amino acids was inhibited by the cell permeable calcium chelator BAPTA-AM while thapsigargin, which releases intracellular calcium, activated mTORC1 activity. Moreover, it was shown that the activation of mTORC1 by amino acids was inhibited by antagonists of CaM or its knockdown using siRNA, suggesting that CaM is required for mTORC1 activity. The underlying mechanism by which calcium and CaM regulate mTORC1 was attributed to the binding of calcium-activated CaM to the hVps34, leading to the activation of its kinase activity. While the sensitivity of mTORC1 to BAPTA-AM and CaM antagonists have been reproducibly observed, ensuing studies have cast some doubt on the notion that hVps34 is a key mediator of calcium and CaM in the regulation of mTORC1 in similar and other cellular systems ([@bib29]; [@bib43]).

In a previous study, we found that small molecules that are known to induce Niemann-Pick Disease Type C (NPC) phenotype inhibited mTOR ([@bib41]). Independently, it has also been reported that NPC cells showed significant defects in lysosomal calcium homeostasis ([@bib25]; [@bib33]). Cells that have mutations in or deficient mucolipin transient receptor potential (TRP) channel 1 (TRPML1) display altered Ca^2+^ homoeostasis similar to that seen in NPC cells ([@bib4]; [@bib8]; [@bib34]). Cells treated with chemical NPC inducers exhibited reduced TRPML1-mediated lysosomal Ca^2+^ release in response to a TRPML1 agonist, indicating dysfunction of this calcium channel. Furthermore, it has been shown that TRPML1 homolog in fly is required for TORC1 activation and fusion of amphisomes with lysosomes, and the inhibition of TORC1 can be rescued by feeding fly larvae with a high-protein diet ([@bib39]; [@bib35]). Furthermore, TORC1 also exerts reciprocal control on TRPML function, establishing the connection between TRPML and TORC1 signaling pathway in fly cells. Whether TRPML1 regulates mTORC1 signaling pathway in mammalian cells remains unknown. Putting these findings together, we hypothesized that a defect in lysosomal calcium homeostasis in NPC cells might be responsible for the observed inhibition of the mTOR signaling pathway.

We validated our hypothesis by demonstrating that depletion of TRPML1 inhibits mTORC1 while overexpression or pharmacologic activation of TRPML1 activates mTORC1. We traced the likely site of regulation of mTORC1 pathway by calcium and CaM by determining the sensitivity of mTORC1 activity to BAPTA-AM and CaM antagonists in response to various upstream activators of the kinase complex and narrowed it to mTORC1 itself. We found that CaM interacted with mTORC1 and activated its kinase activity. Together, these findings shed significant new light on mTORC1 signaling pathway and offer a unifying mechanism that accounts for most, if not all, earlier observations implicating calcium and CaM in the regulation of mTORC1 by different upstream activators in distinct cellular context.

Results {#s2}
=======

TRPML1 is required for the activation of mTORC1 {#s2-1}
-----------------------------------------------

To determine whether TRPML1 is required for mTORC1 signaling, HEK293T cells were transduced with lentiviral shRNA targeting human TRPML1 (Sh1 and Sh2) or a scrambled shRNA (Scr). Due to lack of reliable hTRPML1 antibodies, the knockdown efficiency was assessed by RT-qPCR ([Figure 1a](#fig1){ref-type="fig"}, bottom panel) as well as indirectly by the expression level of ectopically expressed EGFP-TRPML1. The activity of mTORC1, as judged by the phosphorylation of S6K, was significantly inhibited upon TRPML1 knockdown, while the phosphorylation of Akt (T308) was not affected ([Figure 1a](#fig1){ref-type="fig"}). To determine whether the mTOR inhibition caused by TRPML1 knockdown was due to blockade of lysososmal calcium release, we performed a rescue experiment in Human Umbilical Vein Endothelial Cells (HUVEC) ([Figure 1b](#fig1){ref-type="fig"}) and HEK293T ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}) using thapsigargin, a sarco/endoplasmic reticulum Ca^2+^-ATPase inhibitor that increases cytosolic calcium concentrations ([@bib27]). Indeed, the inhibition of mTORC1 activity by TRPML1 knockdown was rescued by thapsigargin, suggesting that mTORC1 inhibition was due, in large part, to the lack of lysosomal calcium release. Moreover, knocking down TRPML1 also attenuated the activation of mTORC1 by insulin ([Figure 1c](#fig1){ref-type="fig"}), leucine ([Figure 1d](#fig1){ref-type="fig"}) as well as overexpression of constitutively active RagA or RagC ([Figure 1e](#fig1){ref-type="fig"}). Furthermore, we determined the phosphorylation of S6K in normal human fibroblasts (TRPML1 +/+) and fibroblasts from a mucolipidosis IV patient (TRPML1 -/-). Compared with TRPML1 +/+ human fibroblasts, TRPML1 -/- cells showed decreased phosphorylation of S6K ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}). Interestingly, this inhibition was partially reversed by leucine compared with that in wild type cells ([Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"}). However, the treatment of thapsigargin fully restored the phosphorylation of S6K ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}), suggesting that in mammalian cells, the decrease in mTORC1 activity in TRPML1 mutant cells is not only due to the incomplete autophagy that has been reported in *Drosophila* ([@bib39]). In addition, knockdown of other lysosomal channels, such as TPC2 and P2X4, did not significantly inhibit mTORC1 signaling ([Figure 1---figure supplement 1d](#fig1s1){ref-type="fig"}), indicating that the decreased mTOR activity upon TRPML1 knockdown was not due to the dysregulation of the structure of the endolysosmal system, and as one of the lysosomal calcium channels, TRPML1 may play a more dominant role in the regulation of mTORC1 signaling.10.7554/eLife.19360.002Figure 1.TRPML1 is required for the full activation of mTORC1.(**a**) HEK293T cells were transduced with lentiviral scrambled shRNA (Scr) and shRNA targeting human TRPML1 (Sh1 and Sh2), respectively. To assess the knockdown efficiency, a fraction of transduced cells were transfected with EGFP-TRPML1. After 24 hr, transfected or untransfected cells were lysed and subjected to immunoblotting. Untransfected cells were used to detect p-S6K, S6K and p-Akt, and transfected cells were used to detect GFP and GAPDH. RT-qPCR was also performed to evaluate the knockdown efficiency (bottom panel) (mean ± s.d., n = 2 independent experiments). (**b**) Scrambled shRNA or TRPML1 shRNA-transduced HUVEC were treated with vehicle control or thapsigargin (5 μM) for an additional 2 hr. Cells were lysed and subjected to immunoblotting. Knockdown efficiency was assessed by RT-qPCR (right panel). The bottom panel of plots shows the percentage of p-S6K and p-4EBP1 levels compared with scramble shRNA transduced vehicle control treated HUVEC normalized by GAPDH loading control (mean ± s.d., n = 2 independent experiments). (**c** and **d**) Scrambled shRNA or TRPML1 shRNA transduced HEK293T cells were deprived for 24 hr of serum (**c**) or 3 hr of leucine (**d**) and, where indicated, were stimulated with 600 nM insulin or 52 μg/ml leucine for 10 min. Simultaneously, another fraction of scrambled shRNA or TRPML1 shRNA-transduced cells were transfected with EGFP-TRPML1 for 24 hr. Cells were lysed and subjected to immunoblotting. The plots show the percentage of p-S6K levels compared with scramble shRNA transduced serum (**c**) or leucine (**d**) starved HEK293T cells normalized by total S6K control (mean ± s.d., n = 2 independent experiments, respectively). (**e**) Scrambled shRNA or TRPML1 shRNA-transduced HEK293T cells were transfected with Rag AQ66A or Rag CS75L for 24 hr. Cells were lysed and subjected to immunoblotting. The plot shows the percentage of p-S6K level compared with scramble shRNA transduced empty vector transfected HEK293T cells normalized by total S6K control. (mean ± s.d. for n = 3 independent experiments).**DOI:** [http://dx.doi.org/10.7554/eLife.19360.002](10.7554/eLife.19360.002)10.7554/eLife.19360.003Figure 1---figure supplement 1.Effects of TRPML1 on mTORC1 activation.(**a**) Scrambled shRNA or TRPML1 shRNA-transduced HEK293T cells were treated with vehicle control or thapsigargin (5 μM) for 2 hr, respectively. Cells were lysed and subjected to immunoblotting. RT-qPCR (right panel) and EGFP-TRPML1 transfected cells were used to evaluate the knockdown efficiency. (**b**) Healthy human fibroblast or mucolipidosis IV patient's fibroblasts (TRPML-/-) were treated with vehicle control or thapsigargin (5 μM) for 2 hr, respectively. Cells were lysed and subjected to immunoblotting. The plot shows the percentage of p-S6K level compared with vehicle control treated wild type human fibroblasts normalized by total S6K control. (mean ± s.d. for n = 3 independent experiments). (**c**) WT and mucolipidosis IV patient's fibroblasts (TRPML-/-) were treated with vehicle control or leucine for 10 min. Cells were lysed and subjected to immunoblotting. The plot shows the percentage of p-S6K level compared with vehicle control treated TRPML-/- human fibroblasts normalized by total S6K control. (mean ± s.d. for n = 2 independent experiments). (**d**) Lentivirus carrying scrambled shRNA, TRPML1 shRNA, TPC2 shRNA or P2X4 shRNA transduced HEK293T cells were lysed and subjected to immunoblotting. RT-qPCR (bottom panel) was used to evaluate the knockdown efficiency of TPC2.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.003](10.7554/eLife.19360.003)

Having shown that TRPML1-mediated lysosomal calcium release is necessary for mTORC1 activity, we then turned to the reciprocal question of whether an increase in lysosomal calcium release through TRPML1 could stimulate mTORC1. Thus, HEK293T cells were transfected with expression plasmids for EGFP-TRPML1 and its non-conducting pore mutant (D471K/D472K) EGFP-TRPML1 (KK), respectively. The phosphorylation of S6K was slightly but significantly increased by overexpression of wild type TRPML1 but not the non-conducting pore mutant TRPML1 (KK) ([Figure 2a](#fig2){ref-type="fig"}). Next, we treated HEK293T cells with TRPML1 agonist MLSA1 ([@bib33]; [@bib11]). The phosphorylation of S6K was increased by MLSA1 in a dose-dependent manner ([Figure 2b](#fig2){ref-type="fig"}). In contrast, MLSA1 failed to increase the phosphorylation of S6K in the cells transduced with lentiviral TRPML1 shRNA, or pretreated with bafilomycin A1 or Glycyl-L-phenylalanine 2-naphthylamide (GPN), suggesting that the increase in S6K phosphorylation induced by MLSA1 was mediated by calcium released through TRPML1 ([Figure 2c,d](#fig2){ref-type="fig"}). Upon amino acids stimulation, mTOR translocated from the cytosol to the lysosome, colocalizing with EGFP-TRPML1 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), indicating that the activation of TRPML1 acted independently of the translocation of mTORC1 induced by amino acids. The upregulated TRPML1 has been reported to promote autophagy ([@bib37]; [@bib28]; [@bib39]). To determine if activation of mTORC1 in response to TRPML1 overexpression was due to up-regulated autophagy, we overexpressed constitutively active Rab7A (Q67L) and dominant negative Rab7A (T22N) in HEK293T cells ([@bib17]; [@bib16]). As shown in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, overexpression of neither constitutively active nor dominant negative Rab7A affected mTORC1 signaling, while overexpression of TRPML1 plus MLSA1 treatment stimulated the phosphorylation of S6K, suggesting that the activated mTORC1 by TRPML1 stimulation was not mediated through autophagy.10.7554/eLife.19360.004Figure 2.Overexpression or pharmacological stimulation of TRPML1 activates mTORC1 signaling pathway.(**a**) HEK293T cells (80% confluency) were transfected with EGFP vector, EGFP-TRPML1 or its non-conducting pore mutant (D471K/D472K) EGFP-TRPML1 (KK) for 20 hr. Cells were lysed and subjected to immunoblotting. The plot shows the percentage of p-S6K levels compared with vector transfected cells normalized by total S6K control (mean ± s.d., n = 3 independent experiments). (**b**) HEK293T cells were treated with different concentrations of ML-SA1 for 3 hr. Cells were lysed and subjected to immunoblotting. The plot shows the dose-response curve of ML-SA1 normalized by total S6K. (**c**) Scrambled shRNA or TRPML1 shRNA transduced HEK293T cells were treated with varying concentrations of MLSA1 for 3 hr. Cells were lysed and subjected to immunoblotting. The plot shows the percentage of p-S6K levels compared with scramble shRNA transduced vehicle control treated 293T cells normalized by GAPDH loading control (mean ± s.d., n = 3 independent experiments). (**d**) HEK293T cells were pretreated with bafilomycin A1 (1 μM) or GPN (200 μM) for 1 hr, followed by treatment with or without MLSA1 for an additional 1.5 hr. Cells were lysed and subjected to immunoblotting. The plot shows the percentage of p-S6K levels compared with vehicle control normalized by GAPDH loading control (mean ± s.d., n = 3 independent experiments). \*p\<0.05, \*\*p\<0.01, n.s. no significant difference.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.004](10.7554/eLife.19360.004)10.7554/eLife.19360.005Figure 2---figure supplement 1.Colocalization of EGFP-TRPML1 and mTOR.HEK293T cells were transfected with EGFP-TRPML1 expression plasmid. After 18 hr, cells were treated with MLSA1 (15 μM) for 1 hr, and starved with amino acids for 1 hr, or starved with amino acids for 1 hr and restimulated with amino acids for 15 min. Cells were fixed, stained with anti-mTOR antibody and images were captured using a Zeiss LSM 700 confocal microscope.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.005](10.7554/eLife.19360.005)10.7554/eLife.19360.006Figure 2---figure supplement 2.Effects of constitutively active or dominant negative Rab 7A.HEK293T cells were transfected with EGFP-ML1, EGFP-Rab7A (Q67L) or EGFP-Rab7A (T22N). After 19 hr, the cells transfected with EGFP-ML1 were treated with MLSA1 (20 μM) for 1 hr. Cells were lysed and subjected to immunoblotting.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.006](10.7554/eLife.19360.006)

Calcium and CaM are required for activation of mTORC1 {#s2-2}
-----------------------------------------------------

Both intracellular calcium and CaM have been reported to be required for mTORC1 activity ([@bib6]; [@bib12]; [@bib14]; [@bib15]; [@bib29]). We thus treated HEK293T cells with the cytosolic Ca^2+^ chelator BAPTA-AM (BAPTA) or the CaM antagonists W-7 and calmidazolium (CMDZ). In agreement with previous studies ([@bib14]; [@bib18]; [@bib12]; [@bib44]), we observed that BAPTA , W-7 and CMDZ inhibited phosphorylation of S6K in a dose-dependent manner with IC~50~ values of 3.96 ± 1.30 μM, 21.59 ± 1.81 μM and 10.36 ± 0.59 μM, respectively ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In comparison to S6K, phosphorylation of Akt (S473), the substrate of mTORC2, was also inhibited by CMDZ and W-7, but at much higher concentrations (EC~50~ values of 27.21 ± 9.82 μM and 45.91 ± 9.61 μM, respectively) compared with that of p-S6K, while BAPTA did not show appreciable inhibition to p-Akt (S473) ([Figure 3---figure supplement 1c](#fig3s1){ref-type="fig"}). In addition, CMDZ and BAPTA also showed potent inhibitory effect on mTORC1 signaling pathway in HUVEC and A549 cells ([Figure 3---figure supplement 2a,b](#fig3s2){ref-type="fig"}), suggesting that mTORC1 is also regulated by Ca^[2+]{.ul}^/CaM in primary and other cancer cells.

Next, we investigated how fast mTORC1 and mTORC2 responded to BAPTA or CMDZ. As shown in [Figure 3a](#fig3){ref-type="fig"}, both CMDZ and BAPTA caused appreciable inhibition of mTORC1 activity within 0.5--1 hr as judged by the phosphorylation of S6K and 4EBP1. In contrast, the phosphorylation of Akt (T308) and its substrate, mTOR (S2448), was not significantly affected by CMDZ until 6 hr post treatment. In addition, CMDZ did not cause significant inhibition of phosphorylation of Akt (S473) until 3 hr after treatment, indicating that the response of mTORC2 to the CaM antagonist has a much slower onset than that of mTORC1 ([Figure 3a](#fig3){ref-type="fig"}, left panel). Although the onset of the effect of BAPTA on 4EBP1 phosphorylation was slightly slower than that of CMDZ, BAPTA did not significantly affect the phosphorylation of either Akt (S473, T308) or mTOR even after 6 hr ([Figure 3a](#fig3){ref-type="fig"}, right panel). These results suggest that CaM regulates both mTORC1 and mTORC2, but the two complexes differ in their sensitivity to CaM and calcium. Interestingly, after a 6-hr treatment with BAPTA, the inhibition of phosphorylation of S6K and 4EBP1 was partially reversed, which is consistent with a previous report that over time upon treatment with BAPTA, a gradual increase in intracellular Ca^2+^ was seen ([@bib38]). The relatively short time required for CMDZ and BAPTA to exert their effects on mTORC1 and their faster onset than those on mTORC2 suggested that the inhibition of mTORC1 likely occurred independently of its upstream signaling events, such as phosphorylation of Akt (T308).10.7554/eLife.19360.007Figure 3.Regulation of mTORC1 by cytosolic calcium and CaM occurs proximal to mTORC1 itself.(**a**) Effects of 10 μM CaM antagonist calmidazolium (CMDZ) or 25 μM cytosolic Ca^2+^ chelator BAPTA-AM (BAPTA) on the phosphorylation of different proteins of the mTOR signaling pathway at different time points. The bottom panel of plots shows the percentage of p-S6K and p-Akt (S473) levels compared with 0 min treated 293T cells normalized by total S6K and total Akt control, respectively (mean ± s.d., n = 3 independent experiments). (**b** and **d**) Effects of CMDZ (10 μM) or BAPTA-AM (25 μM) on the phosphorylation of indicated proteins in response to deprivation and stimulation with leucine (**b**) and insulin (**d**). Cell lysates were prepared from HEK293T cells deprived for 3 hr of leucine (**b**) or 24 hr of serum (**d**) and, where indicated, stimulated with 52 μg/ml leucine or 600 nM insulin for 10 min. CMDZ (10 μM) or BAPTA-AM (25 μM) was added 1 hr prior to cell harvesting. The plots show the percentage of p-S6K levels compared with vehicle control treated leucine (**b**) or serum (**d**) starved HEK293T cells normalized by total S6K control (mean ± s.d., n = 3 independent experiments, respectively). (**c**) Effects of CMDZ (10 μM) on the phosphorylation of S6K in HEK293T cells transfected with constitutively active RagA or RagC in expression vectors. Cell lysates were prepared and subjected to immunoblotting. The plot shows the percentage of p-S6K levels compared with vector transfected vehicle control treated 293T cells normalized by GAPDH loading control (mean ± s.d., n = 3 independent experiments). (**e** and **f**) Effects of 25 μM BAPTA-AM (**e**) and 10 μM CMDZ (**f**) on the phosphorylation state of S6K in HEK293T cells stably expressing constitutively active Rheb as indicated. HEK293T cells were transduced with lentiviral FLAG-tagged Rheb^N153T^, and treated with indicated compounds for 1 hr. Cell lysates were prepared and used for immunoblotting. The plots show the percentage of p-S6K levels compared with vehicle control treated empty lentiviral vector transduced 293T cells normalized by total S6K control (mean ± s.d., n = 2 independent experiments). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001, n.s. no significant difference.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.007](10.7554/eLife.19360.007)10.7554/eLife.19360.008Figure 3---figure supplement 1.Effects of calmodulin antagonist (**a**) calmidazolium (CMDZ), (**b**) W-7 and (**c**) cytosolic Ca^2+^ chelator BAPTA-AM on phosphorylation state of S6K (T389) and Akt (S473).HEK293T cells were treated with different concentrations of indicated compound for 1 hr. The phosphorylation state of S6K and Akt was analyzed by immunoblotting. The plots show the dose-response curve of CMDZ, W-7 and BAPTA normalized by total S6K, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.008](10.7554/eLife.19360.008)10.7554/eLife.19360.009Figure 3---figure supplement 2.Effects of calmodulin antagonist calmidazolium (CMDZ) and cytosolic Ca^2+^ chelator BAPTA-AM on mTOR signaling pathway in HUVEC and A549 cells.HUVEC (**a**) and A549 (**b**) cells were treated with different concentrations of BAPTA or CMDZ for 1 hr. The phosphorylation state of S6K and 4EBP1 was analyzed by immunoblotting. HUVEC (**c**) and A549 (**d**) cells were transduced with lentivirus carrying constitutively active Rheb^N153T^. The transduced cells were treated with BAPTA or CMDZ for 1 hr. The phosphorylation state of S6K was analyzed by immunoblotting.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.009](10.7554/eLife.19360.009)

Regulation of mTORC1 by cytosolic calcium and CaM occurs proximal to mTORC1 itself {#s2-3}
----------------------------------------------------------------------------------

To further explore the level at which Ca^2+^ and CaM regulate mTORC1 signaling, we determined the effects of CMDZ and BAPTA on mTORC1 activation in response to various upstream activating stimuli of mTORC1. Similar to previous observations ([@bib14]), we found that leucine-stimulated mTORC1 activation was inhibited by BAPTA and CMDZ ([Figure 3b](#fig3){ref-type="fig"}, Lanes 4 vs. 2 and 6 vs. 2). The activation of mTORC1 by leucine has been shown to be mediated by the small GTPases RagA/B and RagC/D ([@bib21]), and overexpression of constitutively active RagA^Q66L^/RagC^S75N^ can bypass leucine to activate mTORC1. We found that activation of mTORC1 by either RagA^Q66L^ or RagC^S75N^ remained sensitive to CMDZ ([Figure 3c](#fig3){ref-type="fig"}). Next, we determined whether activation of mTORC1 by insulin was also sensitive to CaM blockade. Although insulin strongly increased the phosphorylation of Akt (T308) ([Figure 3d](#fig3){ref-type="fig"}, Lanes 2), the mTORC1 activity remained sensitive to CMDZ as well as BAPTA-AM ([Figure 3d](#fig3){ref-type="fig"}, Lanes 4 and 6). It has been reported that mTOR is directly bound to and activated by Rheb-GTP ([@bib26]). Thus, we used HEK293T, HUVEC and A549 to produce stable cell lines overexpressing constitutively active Rheb^N153T^ as previously described ([@bib42]), and determined their sensitivity to BAPTA and CMDZ. Rheb^N153T^-induced phosphorylation of S6K remained sensitive to inhibition by BAPTA and CMDZ in HEK293T, HUVEC and A549 cells ([Figure 3e,f](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2c,d](#fig3s2){ref-type="fig"}). Together, these results suggested that the site of regulation of mTORC1 by Ca^2+^ and CaM lies proximal to mTORC1 itself.

CaM interacts with mTOR {#s2-4}
-----------------------

CaM has been previously reported to indirectly interact with mTORC1, and human vacuolar protein sorting 34 (hVps34) was shown to mediate the interaction between CaM and mTORC1 in HeLa cells ([@bib14]). To our surprise, when hVps34 was knocked down in HEK293T cells, binding of CaM to mTOR was not affected ([Figure 4a](#fig4){ref-type="fig"}), neither was the sensitivity of mTORC1 to CaM ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), ruling out hVps34 as a mediator of CaM-mTOR interaction in HEK293T cells. These results raised the possibility that CaM may directly interact with a subunit of the mTORC1 complex, thereby regulating its kinase activity. Indeed, CaM sepharose could pull down mTOR and raptor, but not PRAS40, in a Ca^2+^-dependent manner ([Figure 4b](#fig4){ref-type="fig"}). The interaction between mTOR and CaM was sensitive to detergents and the CaM antagonist W-7 ([Figure 4b](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). However, Ca^2+^ did not affect the assembly of mTORC1 complex ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}), suggesting that one of the interactions of CaM sepharose with mTOR and raptor could be indirect. To identify the subunit in mTORC1 that interacts with CaM, we knocked down raptor and mTOR, respectively, and determined the remaining interaction between each subunit and CaM sepharose ([Figure 4a](#fig4){ref-type="fig"}). Knockdown of raptor had no effect on the pulldown of mTOR by CaM sepharose. In contrast, knockdown of mTOR significantly reduced the binding of raptor as well as mTOR to CaM ([Figure 4a](#fig4){ref-type="fig"}), suggesting that the interaction between mTOR and CaM is independent of raptor.10.7554/eLife.19360.010Figure 4.CaM interacts with mTORC1 and regulates mTORC1 kinase activity in vitro.(**a**) CaM interacts with mTOR independent of hVps34 or raptor. Cell lysates were prepared from HEK293T cells transduced with lentiviral shRNAs targeting human mTOR, raptor, hVps34 or scrambled shRNA, followed by CaM sepharose precipitation in the presence of CaCl~2~ (1 mM) or EGTA (5 mM). The cell lysates and precipitates were analyzed by immunoblotting to detect the indicated proteins. (**b**) Endogenous mTORC1 was pulled down by CaM sepharose in a Ca^2+^-dependent manner. HEK293T cells were lysed in CHAPS buffer, and the lysates were incubated with CaM sepharose in the presence of CaCl~2~ (1 mM) or EGTA (5 mM). The precipitates were analyzed by immunoblotting. (**c** and **d**) Cell lysates were prepared from HEK293T cells in CHAPS buffer, and endogenous mTORC1 was immunoprecipitated by a raptor antibody. ATP (250 μM), Torin1 (100 nM), CMDZ (8 μM), CaM (2 μM) or/and CaCl~2~ (1 mM) were added into the kinase reaction as indicated. Phosphorylation of 4EBP1 (**c**) and S6K (**d**) were detected by immunoblotting. The plots show the fold of change of phosphorylation of 4EBP1 (**c**) or S6K (**d**) compared with control group (first lane) normalized by total GST-tagged protein control. (mean ± s.d., n = 6 and 5 independent experiments, respectively).**DOI:** [http://dx.doi.org/10.7554/eLife.19360.010](10.7554/eLife.19360.010)10.7554/eLife.19360.011Figure 4---figure supplement 1.Effects of calmidazolium (CMDZ) on hVps34 depleted cells.(**a**) HEK 293T cells were transduced with lentivirus carrying scramble shRNA or shRNA targeting hVps34. 96 hr after puromycin selection, cells were treated with vehicle control or CMDZ (10 μM) for 1 hr. (**b**) The same cells in (**a**) were starved with amino acids for 1 hr, and re-stimulated with amino acids for 10 min. Cells were lysed and subjected to immunoblotting.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.011](10.7554/eLife.19360.011)10.7554/eLife.19360.012Figure 4---figure supplement 2.CaM interacts with mTORC1 independently of raptor or hVps34.(**a**) The interaction between CaM and mTORC1 is sensitive to detergents. Cell lysates were prepared from HEK293T cells in lysis buffer containing 1% Triton X-100 or 1% NP-40. Endogenous mTORC1 was precipitated by CaM sepharose in the presence of Ca^2+^ or EGTA. (**b**) The interaction between CaM and mTOR is inhibited by the CaM antagonist W-7. Cell lysates were prepared from HEK293T cells in CHAPS buffer, and endogenous mTOR was precipitated by CaM sepharose in the presence of W-7 or vehicle control.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.012](10.7554/eLife.19360.012)10.7554/eLife.19360.013Figure 4---figure supplement 3.The presence or absence of Ca^2+^ does not affect the association of mTORC1.Cell lysates were prepared from HEK293T in CHAPS buffer, and endogenous mTORC1 was immunoprecipitated by mTOR antibody. Rabbit IgG was used as mock immunoprecipitation.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.013](10.7554/eLife.19360.013)10.7554/eLife.19360.014Figure 4---figure supplement 4.Proposed model of regulation of mTORC1 by TRPML1, lysosomal calcium and CaM.Upon the translocation of mTORC1 onto the lysosome through binding to GTP-Rheb, lysosomal Ca^2+^ released through TRPML1 enriches the local Ca^2+^ concentration, prompting the binding to and activation of CaM, which in turn interacts with mTORC1 and leading to a fully activation of the kinase activity.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.014](10.7554/eLife.19360.014)

Ca^2+^ and CaM activate the kinase activity of isolated mTORC1 complex *in vitro* {#s2-5}
---------------------------------------------------------------------------------

Having shown that CaM binds to mTORC1, we asked the question of whether CaM and Ca^2+^ had a direct effect on the intrinsic kinase activity of isolated mTORC1 complex *in vitro*. Thus, endogenous mTORC1 complex was immunoprecipitated by an anti-raptor antibody, and an *in vitro* kinase assay was performed using purified recombinant 4EBP1 as a substrate ([@bib9]). As shown in [Figure 4c](#fig4){ref-type="fig"}, the phosphorylation of 4EBP1 by immunoprecipitated mTORC1 complex was significantly increased in the presence of both CaCl~2~ (1 mM) and CaM (2 μM), but not CaM alone, indicating that CaM activates mTORC1 kinase activity *in vitro* in a Ca^2+^-dependent manner ([Figure 4c](#fig4){ref-type="fig"}, top left and top right panels, Lanes 1--3, respectively). Importantly, the activation of mTORC1 by Ca^2+^/CaM was inhibited by Torin 1 ([Figure 4c](#fig4){ref-type="fig"}, top left panel, Lane 4), a TOR kinase inhibitor, and CMDZ ([Figure 4c](#fig4){ref-type="fig"}, top right panel, Lane 4), indicating that the phosphorylation of 4EBP1 was dependent on TOR kinase activity and CaM. Similar results were obtained from the *in vitro* kinase assay using purified recombinant S6K as the substrate ([Figure 4d](#fig4){ref-type="fig"}). Together, these results demonstrated that binding of CaM to mTORC1 leads to the stimulation of kinase activity of the mTORC1 complex.

Discussion {#s3}
==========

The work described in this manuscript reveals a novel mechanism of regulation of mTORC1 by lysosomal calcium and CaM ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}), shedding new light on the mTOR signaling pathway. In the current model of mTORC1 activation ([@bib7]; [@bib2]; [@bib10]; [@bib31]), growth factors, energy, and other inputs signal to mTORC1 primarily through the TSC-Rheb axis; amino acids act by regulating the nucleotide state of the heterodimeric Rag GTPases and promoting the translocation of mTORC1 onto lysosomes, where it interacts with and becomes activated by lysosomally-localized, GTP-bound Rheb ([@bib32]). Our results have uncovered another role of lysosomal localization of mTORC1, i.e., to receive localized lysosomal calcium stimulation. Integrating our previous observations ([@bib41]) and the results from the present study, we propose an addition to the current model of mTOR signaling pathway: upon the translocation of mTORC1 onto the lysosome, properly released lysosomal calcium enriches local Ca^2+^ concentration, prompting Ca^2+^ binding to a local population of CaM, which in turn binds mTORC1 and stimulates the kinase activity of the mTORC1 complex.

The depletion of the homolog of TRPML1, TRPML in *Drosophila*, results in decreased TORC1 signaling, which was attributed to incomplete autophagy, and was completely reversed by feeding fly larvae with a high-protein diet ([@bib39]; [@bib35]). However, we showed that in TRPML1-knockdown mammalian cells or mucolipidosis IV human fibroblasts, the inhibited mTORC1 signaling was only partially reversed by leucine or overexpression of constitutively active Rag GTPase, suggesting that there is a difference in the mechanisms of regulation of mTOR by Ca^2+^/CaM between mammalian and fly cells. Interestingly, thapsigargin, which increases cytosolic Ca^2+^, could completely restore phosphorylation of S6K in TRPML1 deficient cells to the control level. Given that increased cytosolic Ca^2+^ also positively regulates the Ca^2+^-dependent fusion of late-endosomes and autophagosomes to lysosomes ([@bib13]; [@bib25]; [@bib39]), the rescue effect of thapsigargin might be due to the combined effects of autophagy as well as the direct stimulation of mTORC1 by Ca^2+^/CaM in mammalian cells. On the other hand, TRPML1 is significantly upregulated under amino acids starvation ([@bib37]), when mTORC1 dissociates from the lysosomal surface and becomes inactive, indicating that mTORC1 and TRPML1 may form reciprocal regulation loop. In addition, it has been recently reported that under starvation, lysosomal Ca^2+^ release through TRPML1 activates local calcineurin, a Ca^2+^, CaM-dependent protein phosphatase, which dephosphorylates TFEB and promotes its nuclear translocation as well as regulates lysosomal biogenesis ([@bib28]), suggesting another local function of lysosomal Ca^2+^.

Our model of regulation of mTORC1 by Ca^2+^ and CaM differs from that proposed in a previous report ([@bib14]), even though some of the experimental observations are in agreement. Similar to previous reports ([@bib14]; [@bib18]; [@bib12]), we found that mTORC1 activity is sensitive to inhibition by BAPTA-AM and CaM antagonist CMDZ ([Figure 3](#fig3){ref-type="fig"}), suggesting that both intracellular calcium and CaM are required for mTORC1 activation. However, the precise mechanism of regulation of mTORC1 by calcium and CaM is distinct in our new model. First, we demonstrated that the lysosomal pool of calcium plays a unique and critical role in mTORC1 activation in mammalian cells. In earlier studies, however, the sources of calcium have been only suggested to be extracellular ([@bib6]; [@bib14]) or conventional intracellular calcium stores such as the ER ([@bib18]; [@bib12]; [@bib44]). Second, a previous study showed the CaM associates with mTORC1 complex through hVps34, and calcium and CaM activate mTORC1 via hVps34 activation ([@bib14]). In an independent study, it was shown that hVps15, but not Ca^2+^/CaM, activates hVps34 ([@bib43]). Similarly, we also found that knockdown of hVps34 had no effect on the interaction between CaM and mTORC1 in HEK293T cells, ruling out involvement of hVps34 in the regulation of mTORC1 via Ca^2+^/CaM, at least in this cell type. We surmise that most of the previous results implicating calcium or CaM in the regulation of mTORC1 may be explained by our current model.

In previous studies, *in vitro* kinase assay of mTORC1 used EDTA in immunoprecipitation buffer ([@bib19], [@bib20]), which precluded the detection of any regulatory effect of calcium and CaM. By performing the mTOR kinase assay in the absence or presence of calcium and CaM *in vitro*, we were able to observe a dramatic activation of mTORC1 by calcium and CaM, revealing the functional consequence of the binding of CaM to mTOR\--activation of its intrinsic kinase activity. As such, mTOR is a new type of atypical CaM-dependent kinase. The newly uncovered roles of lysosomal calcium and CaM in the regulation of mTOR signaling not only fill a gap in our understanding of this fundamental signaling pathway, but also offer new molecular targets for discovering and developing novel mTOR inhibitors.

Materials and methods {#s4}
=====================

Cell lines and tissue culture {#s4-1}
-----------------------------

HEK293T (RRID: [CVCL_0063](https://scicrunch.org/resolver/CVCL_0063), purchased from ATCC, the identity has been authenticated using STR profiling) and A549 (RRID: [CVCL_0023](https://scicrunch.org/resolver/CVCL_0023), purchased from ATCC, the identity has been authenticated using STR profiling) cells were cultured in low glucose DMEM (Life Technology) supplemented with 10% FBS (Life Technology). Healthy human fibroblasts (Coriell Insititute, GM03440) and mucolipidosis IV human fibroblasts (Coriell Insititute, GM02048) were cultured in EMEM (ATCC) supplemented with 15% FBS. HUVEC (purchased from Lonza) were cultured in EGM media (Lonza). All cells were cultured at 37°C with the presence of 5% CO~2~. All cell lines were tested for mycoplasma contamination and showed negative result. HEK293T and A549 cells have been authenticated using STR profiling at Johns Hopkins Genetic Resources Core Facility. Match percent was searched and compared with American Tissue Culture Collection database. HEK293T cells showed 100% matching to ATCC HEK293T reference profiling (ATCC number CRL-3216), and A549 cells showed 93% matching to ATCC A549 reference profiling (ATCC number CCL-185). Given ≥ 80% level of matching indicates that the cell lines are related, we concluded that both HEK293T and A549 cell lines are authenticated.

Leucine starvation and stimulation of the cells {#s4-2}
-----------------------------------------------

Almost confluent cultures in 6-well plates were washed once with leucine-free low glucose DMEM (US Biological), incubated in leucine-free DMEM for 3 hr, and stimulated with 52 μg/ml leucine for 10 min. For those cells treated with calmidazolium (CMDZ, Cayman Chemical) or BAPTA-AM (Cayman Chemical), compounds were added 1 hr prior to cell harvesting. Cells were processed for biochemical assays as described below.

Growth factor starvation and insulin stimulation of the cells {#s4-3}
-------------------------------------------------------------

Almost confluent cultures in 6-well plates were washed once with FBS-free DMEM, incubated in FBS-free DMEM for 24 hr, and stimulated with 600 nM insulin (Life Technology) for 10 min. For those cells treated with calmidazolium (CMDZ) or BAPTA-AM, compounds were added 1 hr prior to cell harvesting. Cells were processed for biochemical assays as described below.

Immunoblotting analysis {#s4-4}
-----------------------

After indicated treatments, cells were washed once with ice-cold PBS and lysed in ice-cold RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na~2~EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na~3~VO~4~, 1 µg/ml leupeptin). After brief sonication, the cell debris was removed by centrifugation at 13,000 rpm for 10 min in a microfuge, and the protein amount in the supernatant was quantified and mixed with a proper volume of 5x SDS loading buffer. Proteins were then separated by SDS-PAGE and transferred to nitrocellulose membranes. After blocking at room temperature for 1 hr, membranes were immunoblotted with anti-p-S6K (T389) (1:1000, Cell Signaling Technology, Cat. 9205, RRID: [AB_330944](https://scicrunch.org/resolver/AB_330944)), p-Akt (T308) (1:1000, Cell Signaling Technology, Cat. 9275, RRID: [AB_329828](https://scicrunch.org/resolver/AB_329828)), p-Akt (S473) (1:1000, Cell Signaling Technology, Cat. 9271, RRID: [AB_329825](https://scicrunch.org/resolver/AB_329825)), p-4EBP1 (S65) (1:1000, Cell Signaling Technology, Cat. 9451, RRID: [AB_330947](https://scicrunch.org/resolver/AB_330947)), p-mTOR (S2448) (1:1000, Cell Signaling Technology, Cat. 2971, RRID: [AB_330970](https://scicrunch.org/resolver/AB_330970)), mTOR (1:1000, Cell Signaling Technology, Cat. 2983, RRID: [AB_2105622](https://scicrunch.org/resolver/AB_2105622)), Akt (1:1000, Cell Signaling Technology, Cat. 9272, RRID: [AB_329827](https://scicrunch.org/resolver/AB_329827)), raptor (1:1000, Cell Signaling Technology, Cat. 2280, RRID: [AB_10830734](https://scicrunch.org/resolver/AB_10830734)), PRAS40 (1:1000, Cell Signaling Technology, Cat. 2610, RRID: [AB_916206](https://scicrunch.org/resolver/AB_916206)), hVps34 (1:1000, Cell Signaling Technology, Cat. 3811, RRID: [AB_2062856](https://scicrunch.org/resolver/AB_2062856)), HA tag (1:1000, Santa Cruz Biotechnology, Cat. sc-7392, RRID: [AB_627809](https://scicrunch.org/resolver/AB_627809)), myc tag (1:1000, Santa Cruz Biotechnology, Cat. sc-40, RRID: [AB_627268](https://scicrunch.org/resolver/AB_627268)), FLAG tag (1:5000, Sigma, Cat. F1804, RRID: [AB_262044](https://scicrunch.org/resolver/AB_262044)), GFP (1:1000, Santa Cruz Biotechnology, Cat. sc-9996, RRID: [AB_627695](https://scicrunch.org/resolver/AB_627695)), S6K (1:1000, Santa Cruz Biotechnology, Cat. sc-8418, RRID: [AB_628094](https://scicrunch.org/resolver/AB_628094)), GAPDH (1:1000, Santa Cruz Biotechnology, Cat. sc-20357, RRID: [AB_641107](https://scicrunch.org/resolver/AB_641107)) at 4°C overnight with the primary antibodies, followed by incubation with HRP-conjugated anti-mouse (1:10000, GE Healthcare, Cat. NXA931, RRID: [AB_772209](https://scicrunch.org/resolver/AB_772209)), anti-rabbit (1:10000, GE Healthcare, Cat. NA934, RRID: [AB_772206](https://scicrunch.org/resolver/AB_772206)) or anti-goat IgG (1:10000, Santa Cruz Biotechnology, Cat. sc-2020, RRID: [AB_631728](https://scicrunch.org/resolver/AB_631728)) at room temperature for 1 hr. Antibody-protein complexes were detected using enhanced chemiluminescence (ECL) immunoblotting detection reagent. The band intensity was measured using ImageJ software (National Institute of Health, USA)

CaM sepharose precipitation {#s4-5}
---------------------------

Cells were washed once with ice-cold wash buffer (40 mM HEPES \[pH 7.4\], 150 mM NaCl), and lysed in ice-cold lysis buffer (40 mM HEPES \[pH 7.4\], 150 mM NaCl, 0.3% CHAPS or 1% NP-40 or 1% Triton-X100, phosphatase inhibitor cocktail (Sigma) and protease inhibitor cocktail (Roche). The cell debris was removed by centrifugation at 13,000 rpm for 10 min in a microfuge. Five percent of the supernatant was reserved as \'input\', and the rest of the supernatant was equally divided into two groups: one contained 1 mM CaCl~2~, and another one contained 5 mM EGTA. The lysates were incubated with pre-washed CaM sepharose (GE Healthcare) at 4°C for 2 hr with rotation. The beads were washed with CaCl~2~ (1 mM) or EGTA (5 mM) -containing CHAPS (0.3% ) buffer 3 times, and boiled at 95°C for 5 min. Elution of the protein from CaM sepharose was subjected to immunoblotting to analyze the recovery of indicated proteins or peptides.

Immunoprecipitations and in vitro kinase assay {#s4-6}
----------------------------------------------

Cells were washed once with ice-cold wash buffer (40 mM HEPES \[pH 7.4\], 150 mM NaCl), and lysed in ice-cold CHAPS buffer (40 mM HEPES \[pH 7.4\], 150 mM NaCl, 2 mM EDTA, 0.3% CHAPS, phosphatase inhibitor cocktail and protease inhibitor cocktail). The cell debris was removed by centrifugation at 13,000 rpm for 10 min in a microfuge. The soluble fractions of cell lysates were mixed with anti-raptor antibody (4 μg/10 cm dish, Life Technology, Cat. 42--4000, RRID: [AB_2533523](https://scicrunch.org/resolver/AB_2533523)), and the mixtures were incubated with rotation for 1.5 hr at 4°C. 80 μl of a 50% slurry of protein A/G plus-sepharose (Santa Cruz Biotechnology) was then added and the incubation continued for an additional 1 hr. Immunoprecipitates were washed twice with ice-cold CHAPS buffer, and once with mTOR kinase buffer (25 mM HEPES \[pH 7.4\], 50 mM KCl, 10 mM MgCl~2~). The kinase assays were performed as previously described ([@bib19]). CaM (2 μM) or/and CaCl~2~ (1 mM) were added into the kinase reaction as indicated. CMDZ (8 μM) or Torin 1 (100 nM, Cayman Chemical) was incubated with the reaction mixtures 10 min prior to initiating the reaction by addition of 250 μM ATP (Sigma). The phosphorylation states of S6K or 4EBP1 were detected by immunoblotting.

Real-time qPCR {#s4-7}
--------------

HEK293T, HUVEC and A549 cells were transduced with lentivirus carrying scramble shRNA or indicated shRNA. Total RNA was collected using RNeasy Mini Kit (QIAGEN). cDNA was generated with SuperScript III First-Strand kit (Invitrogen), and real-time PCR was carried out using TaqMan Universal Master Mix II (Life Technologies). Real-time PCR primers and probes were from Thermo Fisher Scientific: MCOLN1 FAM (Hs01100653_m1), TPCN2 FAM (Hs01552063_m1). Human GAPDH VIC (Hs02758991_g1) was used as an endogenous control.

cDNA manipulations and mutagenesis {#s4-8}
----------------------------------

Myc-mTOR (Addgene plasmid \# 1861), pRK5-HA GST RagA 66L (Addgene plasmid \# 19300), pRK5-HA GST RagC 75L (Addgene plasmid \# 19305) and HA GST PreScission p70 S6K1 (Addgene plasmid \# 15511) were gifts from David Sabatini. pcDNA3-FLAG-Rheb-N153T (Addgene plasmid \# 19997) was a gift from Fuyuhiko Tamanoi. pcDNA-CaM was a gift from David Yue. TRPML1-HA (Addgene plasmid \# 18825) was a gift from Craig Montell. EGFP-Rab7A Q67L (Addgene plasmid \# 28049) and EGFP-Rab7A T22N (Addgene plasmid \# 28048) were gifts from Qing Zhong.

FLAG-tagged Rheb^N153T^ was amplified by PCR and cloned into the EcoRI site of pLVX-AcGFP-N1 vector. GST-tagged 4EBP1 was amplified by PCR and cloned into a pDEST15-based vector. FLAG-tagged CaM was amplified by PCR and cloned into a pGEX6-based vector. TRPML1 was amplified by PCR and cloned into a pEGFP-based vector. All ligations were performed with Infusion Kit (Clontech Laboratories, Inc.) according to the manufacture's instruction. After sequence verification, these plasmids were used, as described below, in transient cDNA transfections, bacterial protein expression or to produce the lentiviruses needed to generate cell lines stably expressing the proteins.

cDNA transfection-based experiments {#s4-9}
-----------------------------------

For transfection experiments, HEK293T cells were seeded in 6-well plates or 6 cm culture dishes. After 24 hr, cells were transfected with the pRK5-based cDNA expression plasmids indicated in the figures (500 ng of truncated mTOR fragments; 200 ng HA-GST-tagged RagA 66L or RagC 75L, 1000 ng of EGFP-tagged TRPML1, and same amount of proper empty vectors) using Lipofectamine 2000 (Life Technology) according to the manufacturer's instructions.

Preparation of p70S6K1, GST-4EBP1 and FLAG-CaM for Use in mTORC1 Kinase Assays {#s4-10}
------------------------------------------------------------------------------

HA-GST-PreScission-p70 S6K1 was transfected into HEK293T cells as described above, and after 48 hr the cells were treated with 20 μM LY294002 for 1 hr prior to cell harvesting and lysis. HA-GST-PreSciss-S6K1 was purified as described ([@bib3]). The purified protein was stored at −20°C in 20% glycerol.

GST-fused 4EBP1 protein was expressed and purified from BL21 (DE3) *Escherichia coli*. Bacteria were grown to an OD of 0.8 and induced for 16 hr at 18°C with 0.5 mM IPTG (American Bioanalytical). Bacteria were pelleted, and lysed in ice-cold PBS containing 1% Triton X-100, 1mg/mL lysozyme (Sigma-Aldrich) and protease inhibitor cocktail by sonication. Cell debris was cleared by centrifugation. The supernatant was mixed with pre-equilibrated glutathione sepharose 4B resin for 1 hr at 4°C with rotation. After gentle centrifugation, GST-4EBP1 was eluted by 10 mM reduced glutathione, and the protein sample was desalted by PD-10 desalting columns and then eluted by the elution buffer (150 mM NaCl, 40 mM HEPES \[pH 7.4\]). The purified protein was stored at −20°C in 20% glycerol.

GST-FLAG-CaM protein was expressed and purified as GST-4EBP1. GST tag was removed by PreScission (GE Healthcare) according to the manufacturer's instruction. The purified protein was stored at −20°C in 20% glycerol.

Mammalian lentiviral shRNAs {#s4-11}
---------------------------

TRC lentiviral shRNAs targeting hTRPML1, mTOR, hVps34 and raptor were obtained from Sigma. The TRC number for each shRNA is as follows:

Human mTOR shRNA \#1: TRCN0000038677

Human mTOR shRNA \#2: TRCN0000039785

Human raptor shRNA \#1: TRCN0000039772

Human raptor shRNA \#2: TRCN0000010415

Human TRPML1 shRNA \#1: TRCN0000083297

Human TRPML1 shRNA \#2: TRCN0000083296

Human hVps34 shRNA \#1: TRCN0000037794

Human hVps34 shRNA \#2: TRCN0000037795

Human TPC2 shRNA \#1: TRCN0000043919

Human TPC2 shRNA \#2: TRCN0000043921

Human P2X4 shRNA \#1: TRCN0000044960

Human P2X4 shRNA \#2: TRCN0000044962

Lentivirus production and cell transduction {#s4-12}
-------------------------------------------

HEK293T cells were seeded in 15-cm culture dishes. When 50--70% confluent, the cells were co-transfected with 9 μg lentiviral vector (empty, lentiviral vector containing sequences expressing indicated proteins, scramble shRNA or shRNA targeting indicated proteins) + 6 μg pspAX~2~ + 3 μg pMD~2~G using lipofectamine 2000 according to manufacturer's instructions. After 24 hr, 48 hr and 72 hr, the supernatants were harvested, respectively, and concentrated using PEG6000 as described before ([@bib22]). The concentrated virus was stored at −80°C.

HEK293T or HUVEC cells were seeded in 10 cm culture dishes. When cells were 40% confluent, concentrated lentiviral solutions were added into the cell culture medium. After 48 hr, cells were treated with antibiotics to select transduced cells.

Immunostaining {#s4-13}
--------------

Cells were fixed with 4% (wt/vol) paraformaldehyde in PBS for 20 min at room temperature (RT). After wash, cells were permeabilized by PBS/0.5% Triton X-100 and incubated at RT for 10 min. After blocking, cells were incubated with anti-mTOR antibody (1:150, Cell Signaling Technology, Cat. 2983) at 4°C overnight, followed by incubating with Alexa Fluor 568 (1:500, Life technologies, Cat. A11011) for 1 hr at RT. Images were captured using a Zeiss LSM 700 confocal microscope.

Data analysis {#s4-14}
-------------

All graphs were created using GraphPad Prism software, and statistical analysis was performed with GraphPad Prism. Data are presented as the mean ± s.d. Two-tail t-test statistical comparisons were made using ANOVA. A *P* value \< 0.05 was considered statistically significant. No statistical method was used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Regulation of mTORC1 by Lysosomal Calcium and Calmodulin\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, including Jonathan S Marchant (Reviewer \#3), and the evaluation has been overseen by a Reviewing Editor and Kevin Struhl as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

All reviewers agree that the discovery of a TRPML-mediated lysosomal Ca^2+^ release mechanism that is necessary for MTORC1 activation is a highly significant advance, and your data are consistent with this conclusion. However, there are a few major concerns that would require confirmation with additional data to substantiate this conclusion and publication in *eLife*:

1\) Specificity of the effects you observe for TRPML1: As TRPML1 knockdown is well known to dysregulate the structure of the endolysosmal system, would similar effects occur if other endolysosomal channels were impaired -- TPCs (also a MTORC partner), P2X receptors? Are similar effects seen e.g. with state locked rab constructs?

2\) Ca^2+^ signaling autonomous to the lysosome: To substantiate the model for a localized acidic Ca^2+^ store, effect compounds that more selectively target acidic Ca^2+^ stores -- e.g. bafilomycin, GPN, NAADP-AM -- need to be used in experiments. Also, there is little supporting evidence from immunolocalization/imaging to address conditions of mTORC recruitment to TRPML1 positive vesicles versus TRPML1 activity?

3\) Signaling effects of VPS34: The effect on S6-P, 4EBP-P, and Akt-473-P after knockdown of VPS34 +/- the CMDZ should be tested. Also, the role of mTOR Complex 2 is not probed directly throughout, because Akt 308-P rather than Akt-473-P is probed ([Figure 3D](#fig3){ref-type="fig"}). The Akt-473-P blot should be included wherever possible.
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Author response

*\[...\] All reviewers agree that the discovery of a TRPML-mediated lysosomal Ca^2+^ release mechanism that is necessary for MTORC1 activation is a highly significant advance, and your data are consistent with this conclusion. However, there are a few major concerns that would require confirmation with additional data to substantiate this conclusion and publication in eLife:*

*1) Specificity of the effects you observe for TRPML1: As TRPML1 knockdown is well known to dysregulate the structure of the endolysosmal system, would similar effects occur if other endolysosomal channels were impaired -- TPCs (also a MTORC partner), P2X receptors? Are similar effects seen e.g. with state locked rab constructs?*

We conducted experiments to address the specificity of the effects of TRPML1. As TPC2 and P2X4 receptors are mainly localized on lysosomes, we knocked down TPC2 and P2X4 using two different shRNA sequences for each. We also used scramble shRNA, shRNA targeting TRPML1 or BAPTA-AM treatment as controls. As shown in revised [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"} (left panel), the knockdown efficiency of the two shRNA sequences targeting human TPC2 was about 60% -- 70% as judged by q-PCR, consistent with the validation data provided by Sigma-Aldrich from which we purchased the shRNA constructs. The knockdown of TPC2 or P2X4 (right panel) did not significantly inhibit the phosphorylation of S6K, while the knockdown of TRPML1 and treatment with BAPTA-AM did, which is consistent with our previous results. In addition, we previously showed that thapsigargin reversed the inhibition of phosphorylation of S6K by TRPML1 knockdown. These pieces of evidence suggest that the effect we observed from TRPML1 knockdown was not due to the dysregulation of the endolysosomal structure. However, we cannot completely rule out the possibility that TPC2 or P2X4, as lysosomal calcium channels, may play a role in regulating mTORC1, given that the knockdown was not complete.

As per reviewers' suggestion, we also overexpressed constitutively active Rab7A (Q67L) and dominant negative Rab7A (T22N) in HEK293T cells, given that Rab7A plays an important role in positively regulating autophagy (Jäger S et al., Journal of cell science 2004, 117, 4837-4848; Hyttinen JM et al., Biochimica et biophysica acta 2013, 1833, 503-510). As shown in revised [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, neither of overexpression of constitutively nor dominant negative Rab7A affected mTORC1 signaling, while overexpression of TRPML1 plus MLSA1 treatment stimulated the phosphorylation of S6K, indicating that the activation of mTORC1 by TRPML1 stimulation was not due to the upregulation of autophagy. We have included these results in our revised manuscript.

*2) Ca^2+^ signaling autonomous to the lysosome: To substantiate the model for a localized acidic Ca^2+^ store, effect compounds that more selectively target acidic Ca^2+^ stores -- e.g. bafilomycin, GPN, NAADP-AM -- need to be used in experiments. Also, there is little supporting evidence from immunolocalization/imaging to address conditions of mTORC recruitment to TRPML1 positive vesicles versus TRPML1 activity?*

Bafilomycin A1 is an inhibitor of vacuolar-type H^+^-ATPase, and it prevents the re-acidification of lysosomes, therefore depletes lysosomal calcium. We pretreated HEK293T cells with bafilomycin for 1 hour, and continuously treated the cells with or without MLSA1 for another hour. As shown in revised [Figure 2D](#fig2){ref-type="fig"}, bafilomycin pretreatment largely abolished the stimulation of mTOR by MLSA1, indicating that the stimulative effect by MLSA1 depends on lysosomal calcium storage. Glycyl-L-phenylalanine 2-naphthylamide (GPN) is a Cathepsin C substrate that induces osmotic lysis of lysosomes and depletes lysosomal calcium. We saw similar effect after GPN pretreatment. These results are consistent with previous report that treatment of cells with bafilomycin A1 or GPN abolished the response of TRPML1 to MLSA1 stimulation (Shen D et al., Nat Commun. 2012, 3:731).

NAADP-AM is reported to bind to TPC2 and induced Ca^2+^ release through TPC2 in TPC2 overexpressed HEK293 cells. However, wild-type cells showed only small and short-lived lysosomal calcium release from native TPC2, and lacked both the ramp-like phase and the secondary transient (Calcraft PJ et al., Nature 2009, 459, 596-600). We did not observe stimulative effect by NAADP treatment in wild type HEK293T cells, likely due to the smaller and shorter calcium release.10.7554/eLife.19360.015Author response image 1.HEK293T cells were treated with NAADP (5 μM) for 1 hr, and were lysed and subjected to immunoblotting.**DOI:** [http://dx.doi.org/10.7554/eLife.19360.015](10.7554/eLife.19360.015)

To test if mTOR is recruited onto TRPML1 positive vesicles, we performed immunofluorescence assay. Because there is no reliable anti-TRPML1 antibody for immunostaining available, we visualized TRPML1 by transfecting HEK293T cells with EGFP-TRPML1 expression plasmid. As shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, when cells were deprived with amino acids, mTOR failed to cluster and was not colocalized with EGFP-TRPML1. However, when the cells were restimulated with amino acids, mTOR clustered and EGFP-TRPML1 largely colocalized with mTOR, indicating that mTOR was recruited to lysosomes and colocalized with TRPML1. These observations are consistent with previous report that TRPML1 colocalized with lysosomes (Cheng X, et al., FEBS Lett. 2010, 584: 2013--2021; Li X et al., Nat Cell Biol. 2016, 18:404-17), and amino acids stimulate the translocation of mTORC1 onto lysosomes with the help of Rag GTPase (Zoncu R et al., Science 2011, 334: 678--683; Sancak Y et al., Cell 2010,141:290-303). This result supports our model in that mTOR is recruited to the lysosome and colocalize with TRPML1 that releases lysosomal calcium locally to activate lysosomally localized mTOR upon stimulation with animo acids.

*3) Signaling effects of VPS34: The effect on S6-P, 4EBP-P, and Akt-473-P after knockdown of VPS34 +/- the CMDZ should be tested. Also, the role of mTOR Complex 2 is not probed directly throughout, because Akt 308-P rather than Akt-473-P is probed ([Figure 3D](#fig3){ref-type="fig"}). The Akt-473-P blot should be included wherever possible.*

To address the first part of this question, we knocked down hVps34 and treated the wild type or knockdown cells with CMDZ or vehicle control. As shown in revised [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, the depletion of hVps34 did not affect the sensitivity of mTOR to CMDZ treatment ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), indicating that the regulation of mTOR by hVps34 is not dependent on CaM. Another study by an independent group also suggested that the activity of hVps34 was independent of Ca^2+^/CaM (Yan Y et al., Biochem J 2009, 417:747-55). However, consistent with previous reports (Byfield MP et al., J Biol Chem. 2005, 280:33076-82; Yoon MS et al., Cell Rep. 2016, 16:1510-7; Nobukuni T et al., Proc Natl Acad Sci U S A. 2005, 102:14238-43.), knockdown of hVps34 largely abolished mTORC1 activation by amino acids stimulation ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}).

For the second part of the question, we agree with the reviewers on the need to assess p-Akt (473) in [Figure 3D](#fig3){ref-type="fig"}. We have added the blot of p-Akt (473) to our revised [Figure 3D](#fig3){ref-type="fig"}, and we also included p-Akt (473) as much as possible in other experiments ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).
